EUVIMEDFaigh amach EUVIMED
Randomisierte kontrollierte Studie

Bone Regeneration in Maxillary Sinus Augmentation using Advanced Platelet-Rich Fibrin (A-PRF) and Plasma Rich in Growth Factors (PRGF): A Pilot Randomized Controlled Trial

Panagiotis Dragonas, Hari S Prasad, Qingzhao Yu, Elizabeth T Mayer, Paul L Fidel

The International Journal of Periodontics & Restorative Dentistry · 2022

DOI: 10.11607/prd.5491 ↗

At a glance

Randomisierte kontrollierte Studie in The International Journal of Periodontics & Restorative Dentistry, 2022. Written by Panagiotis Dragonas and 4 co-authors. Major MEDLINE topics: Sinus Floor Augmentation, Bone Substitutes, Platelet-Rich Fibrin. Cited 3 times so far (Crossref).

AchoimreSubjectsSonraí leabharliostaCiteRelated studies

Abstract (original language)

The purpose of this pilot randomized controlled trial was to analyze and compare the effects of advanced platelet-rich fibrin (A-PRF) and plasma rich in growth factors (PRGF) combined with deproteinized bovine bone mineral (DBBM) on bone regeneration outcomes in maxillary sinus augmentation (MSA) procedures. A total of 15 patients in need of MSA were consecutively recruited. Maxillary sinuses were grafted with DBBM alone (control group), DBBM mixed with A-PRF (PRF group), or DBBM mixed with PRGF (PRGF group). After a 6-month healing period, bone core biopsy samples were collected prior to implant placement for histologic and histomorphometric analyses. The mean percentage of mineralized tissue (MT) was 20.33 ± 11.50 in the control group, 32.20 ± 7.29 for the PRF group, and 34.80 ± 6.83 for the PRGF group, with no statistically significant differences across the three groups (P > .05). The mean percentage of remaining bone grafting material (RBGM) was 24.00 ± 7.94 for the control group, 26.00 ± 7.78 for the PRF group, and 15.80 ± 8.23 for the PRGF group, with no statistically significant differences across the three groups (P > .05). Finally, the mean percentage of nonmineralized tissue (NMT) was 55.66 ± 7.77 for the control group, 41.40 ± 8.32 for the PRF group, and 49.60 ± 5.68 for the PRGF group, with no statistically signifcant differences across the three groups (P > .05). These findings suggest that the addition of A-PRF and PRGF to DBBM does not enhance new bone formation outcomes in maxillary sinus augmentation procedures. Neither of the two platelet concentrates were superior to the other in any of the variables assessed.

Subjects

MeSH terms (MEDLINE)

Sinus Floor AugmentationBone SubstitutesPlatelet-Rich FibrinHumansAnimalsCattleMaxillary SinusPilot ProjectsBone RegenerationBiological ProductsMinerals

Substances

Bone Substitutesbone mealBiological ProductsMinerals

Cite

APA

Dragonas, P., Prasad, H. S., Yu, Q., Mayer, E. T., & Fidel, P. L. (2022). Bone Regeneration in Maxillary Sinus Augmentation using Advanced Platelet-Rich Fibrin (A-PRF) and Plasma Rich in Growth Factors (PRGF): A Pilot Randomized Controlled Trial. The International Journal of Periodontics & Restorative Dentistry. https://doi.org/10.11607/prd.5491

Vancouver

Dragonas P, Prasad HS, Yu Q, Mayer ET, Fidel PL. Bone Regeneration in Maxillary Sinus Augmentation using Advanced Platelet-Rich Fibrin (A-PRF) and Plasma Rich in Growth Factors (PRGF): A Pilot Randomized Controlled Trial. The International Journal of Periodontics & Restorative Dentistry. 2022. doi:10.11607/prd.5491

BibTeX
@article{Dragonas2022,
  author = {Dragonas, Panagiotis and Prasad, Hari S and Yu, Qingzhao and Mayer, Elizabeth T and Fidel, Paul L},
  title = {Bone Regeneration in Maxillary Sinus Augmentation using Advanced Platelet-Rich Fibrin (A-PRF) and Plasma Rich in Growth Factors (PRGF): A Pilot Randomized Controlled Trial},
  journal = {The International Journal of Periodontics & Restorative Dentistry},
  year = {2022},
  doi = {10.11607/prd.5491}
}
Start for free →